A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
Principal Investigator
David SanfordOverview
Body Locations and Systems
LeukemiaDisorders and Conditions
Acute Myeloid LeukemiaClinicalTrials.gov#
NCT04150029Status
RecruitingStudy Start/End
Oct 29, 2020 to Oct 31, 2027Locations
Vancouver General HospitalName/Title
Edward Wong, Research CoordinatorPhone
604-875-4111 ext.22966Email Address
edward.wong@bccancer.bc.caPurpose of Study
The purpose of this study is to investigate the safety and efficacy of the drug MBG453 as treatment for newly diagnosed Acute Myeloid Leukemia patients when used in combination with other anti-cancer treatments.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.